DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer (DISCO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04766190 |
Recruitment Status :
Recruiting
First Posted : February 23, 2021
Last Update Posted : June 1, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Financial Toxicity Cancer Question Prompt List Breast Cancer Prostate Cancer | Behavioral: Group 2: The DISCO App Behavioral: Group 1: Usual Care Behavioral: Group 3: The DISCO App + Booster | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 260 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The research tests the effectiveness of an application-based ("app") communication intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions during clinical interactions, and associated measures. |
Masking: | None (Open Label) |
Primary Purpose: | Health Services Research |
Official Title: | DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer |
Actual Study Start Date : | February 10, 2021 |
Estimated Primary Completion Date : | August 31, 2025 |
Estimated Study Completion Date : | August 31, 2025 |
Arm | Intervention/treatment |
---|---|
Group 1: Usual Care
The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey. The patient will be video recorded at their appointment. The oncologist has agreed to be video recorded. Immediately after this appointment, the patient will be asked to complete another brief survey that takes about 20 minutes. The questions will ask about how the meeting went. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study. |
Behavioral: Group 1: Usual Care
Patients randomized to this arm will receive usual care. |
Group 2: The DISCO App
The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey. The patient will be shown an iPad with an "app" while waiting to see their oncologist. The app includes a short video and asks questions about the patient's financial concerns. The app will give the patient a list of questions the patient may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with the patient's oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting the oncologist, the patient will complete another brief survey. The questions will ask about how the meeting went and what the patient thought of the app. The meeting with the oncologist will not be delayed or changed in any way because of this study. |
Behavioral: Group 2: The DISCO App
Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. |
Group 3: The DISCO App + Booster
The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey. The patient will be shown an iPad with an "app" while waiting to see your oncologist. The app includes a short video and asks questions about your financial concerns. The app will give the patient a list of questions they may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with their oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting their oncologist, they will complete another brief survey. The questions will ask about how the meeting went and what they thought of the app. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study. Two months after that appointment, the patient will be sent a reminder of the information that was presented on the app. |
Behavioral: Group 3: The DISCO App + Booster
Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. Then, 2 months later they will receive an intervention booster in the form of an individually-tailored email to remind patients of the contents of the intervention. |
- Self-efficacy in patient-physician interactions. An example item from the PEPPI scale: How confident are you in your ability to know what questions to ask your doctor? Data will be aggregated using means and standard deviations. [ Time Frame: Immediately after the video-recorded patient-physician interaction ]How efficacious patients feel about communicating with physicians. Scale title: Self-efficacy in patient-physician interactions. Minimum = 1; Maximum = 5; higher is a better outcome.
- Self-efficacy in managing treatment costs An example item from adapted scale: I am confident I can pay for the direct costs of my treatment. Data will be aggregated using means and standard deviations. [ Time Frame: Immediately after video-recorded patient-physician interaction ]How efficacious patients feel about managing their treatment costs. Scale title: Self-efficacy in managing treatment costs. Minimum = 1; Maximum = 5; higher is a better outcome.
- Knowledge of types of treatment cost An example item from the original measure: Cancer treatment may cost me in the following ways? Data will be aggregated using frequency counts. [ Time Frame: Immediately after video-recorded patient-physician interaction ]If patients know the types of cost associated with cancer treatment
- Perceived financial toxicity; Scale title: Adapted Comprehensive score for financial toxicity (COST) measure. [ Time Frame: Immediately after video-recorded patient-physician interaction ]Anticipated financial harm due to treatment cost. Scale title: Adapted Comprehensive score for financial toxicity (COST) measure. Minimum = 0; Maximum = 4; lower is a better outcome.
- Perceived presence of treatment cost discussion [ Time Frame: Immediately after video-recorded patient-physician interaction ]Patient perception that treatment cost discussed with the physician
- Patient self-report of level of satisfaction with any treatment cost discussions with physician assessed via an original scale: satisfaction with any treatment cost discussed with the physician that occurred. [ Time Frame: Immediately after video-recorded patient-physician interaction ]Scale title: Satisfaction with any treatment cost discussed with the physician that occurred. Minimum = 1; Maximum = 5; higher is a better outcome.
- The observed frequency of a cost discussion assessed via an original coding system. Frequency is assessed as the number of distinct cost discussions that occur in each recorded interaction. Higher is a better outcome. [ Time Frame: During the video-recorded patient-physician interaction ]Observation of the frequency of a cost discussion. Minimum = 0; Maximum = undefined.
- Patient-Centered Communication scale. The observed quality of patient-physician communication assessed a validated coding system. Minimum = 1; Maximum =5; higher is a better outcome [ Time Frame: During the video-recorded patient-physician interaction ]Observation of the quality of patient-physician communication.
- Referral to social work/financial navigator [ Time Frame: Immediately after video-recorded patient-physician interaction ]If the patient was referred to a social worker or financial navigator. The number of patients who receive a referral to a social worker or a financial navigator.
- Self-efficacy in patient-physician interactions. An example item from the PEPPI scale: How confident are you in your ability to know what questions to ask your doctor? Data will be aggregated using means and standard deviations. [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]How efficacious patients feel about communicating with physicians. Scale title: Self-efficacy in patient-physician interactions. Minimum = 1; Maximum = 5; higher is a better outcome.
- Self-efficacy in managing treatment costs [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]
How efficacious patients feel about managing their treatment costs. Scale title: Self-efficacy in managing treatment costs. Minimum = 1; Maximum = 5; higher is a better outcome.
An example item from the adapted scale: I am confident I can pay for the direct costs of my treatment.
Data will be aggregated using means and standard deviations.
- Financial toxicity [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]The experience of financial harm due to treatment cost. Rate of patients who indicate they are experiencing financial burden due to cancer treatment costs.
- Follow up with social work/financial navigator [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]
If the patient followed up with social work/financial navigator if referred.
Data will be aggregated using frequency counts.
- Treatment adherence An example item from the Medical Outcomes Study General Adherence measure: I had a hard time doing what the doctor suggested I do for treating my cancer. [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]If the patient adhered to the recommended treatment
- Treatment-cost related adherence [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]If the patient was unable to adhere to treatment due to cost
- Clinical appointment adherence. The rate of appointments a patient is scheduled for and attends. [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]If the patient adhered to clinical appointments
- Assessment of the intervention. [ Time Frame: Immediately after video-recorded patient-physician interaction ]
Patient perceptions of the intervention's usefulness using an original scale.
An example item from the original measure: The DISCO App helped me ask my doctor my cost questions. Minimum = 1; Maximum = 5; higher is a better outcome.
- Assessment of the intervention booster An example item from the original measure: The reminder email or text message was helpful with my cost questions and concerns. [ Time Frame: 1 month after the video-recorded patient-physician interaction ]Patient perceptions of the intervention booster's usefulness
- Intervention presence in video-recorded patient-physician interaction [ Time Frame: During the video-recorded patient-physician interaction ]If the interaction is visible in the video-recorded patient-physician interaction

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Oncologists are eligible if they treat patients with breast, prostate, lung, or colorectal cancers at Karmanos Cancer Institute. Data from oncologists will include their self-report data and video-recorded treatment discussions with participating patients.
- Patients: Must be able to read and write in English; have an email account; and are newly diagnosed with breast, prostate, lung or colorectal cancer (stage I-IV) for which systemic therapy is a likely recommended treatment. Data from patients will include their self-report data, video-recorded treatment discussions with participating oncologists, and medical record data
Exclusion Criteria:
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04766190
Contact: Lauren Hamel, PhD | 313-576-9672 | hamell@karmanos.org |
United States, Michigan | |
Barbara Ann Karmanos Cancer Institute | Recruiting |
Detroit, Michigan, United States, 48201 | |
Contact: Lauren Hamel, PhD 313-576-9672 hamell@karmanos.org | |
Sub-Investigator: Susan Eggly, PhD | |
Sub-Investigator: Seongho Kim, PhD | |
Sub-Investigator: Elisabeth Heath, M.D. |
Principal Investigator: | Lauren Hamel, PhD | Barbara Ann Karmanos Cancer Insitute |
Responsible Party: | Lauren Hamel, Principal Investigator, Barbara Ann Karmanos Cancer Institute |
ClinicalTrials.gov Identifier: | NCT04766190 |
Other Study ID Numbers: |
2020-117 RSG-20-026-01 - CPHPS ( Other Grant/Funding Number: American Cancer Society ) |
First Posted: | February 23, 2021 Key Record Dates |
Last Update Posted: | June 1, 2022 |
Last Verified: | May 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Financial Toxicity Cancer Treatment cost Patient-provider communication |
Financial Stress Stress, Psychological Behavioral Symptoms |